Member Info for sajy

I have been in touch with management and asked for an update on the FDA ODD. The company wrote to the FDA and have been told that due to staff changes at the FDA in 2025 they are playing catch up, hence the delay. They are trying to work through the applications as quickly as possible and hopefully we will hear something soon.

The good news is that it’s nothing on our side that has delayed it.

Looks like poor old Theodoros is still looking for his entry.

For it to hit £2 the following needs to happen in my opinion. First few patients show good safety and signs of efficacy and then we get expressions of interest for either a licensing deal or a takeover. Management have expressed to me that they do not intend to go it alone and there won’t be a shortage of interested parties. At the time it sounded like they had already had early discussions with companies, otherwise why would they say there won’t be a shortage of interested parties.

Hi Positivepat. I consider crtx to be very cheap at this price, it has a Mcap of just £7M which is ridiculous when you consider they are about to start a registration grade phase 2 trial in brain cancer for which there is no current standard of care. Pharma companies with drugs in pre clinical stage have higher Mcap than crtx.

As the trial is open label we have been told by management we will get regular updates and if management announce good safety and early signs of efficacy then I don’t see any reason why we can’t hit £1.

Funny how idiots come on here mentioning placings diluting us when management have clearly stated that we are fully funded for the first part of the trial. Wish some people would actually do some research before they open their mouths.

FDA ODD is due any day and hopefully on that announcement we will hit 20p. Then treatment of first patient next month and we should be getting close to 30p. Then after that it’s all about how good the safety and efficacy is, half decent and expect fireworks. Management have said they will provide regular updates as the trial is open label.

no you wasn’t just saying you ****. you came on here and called me a liar, was that not a personal attack?

your agenda was clear from your first post here. time will tell who was right.

suggest genuine investors ignore both cohen and camkite the pair of ******s, as it is obvious the have missed the entry and are desperate for price to drop so they can buy in. management have said we are fully funded and i believe them. mark my words if management report good safety and early signs of efficacy in the first few patients then this will be above 50p in a flash. just look at what hemo did and we are much more advanced than they were.

Camkite don't come on here shouting your mouth of you pr@t. I was replying to a poster who was saying we would be diluted heavily and comparing to avct. I have spoken to the management and we are fully funded for the first part of the trial and have no intentions of funding the second part of the trial as that would involve a hugh raise. They intend to sign a licensing deal or get taken over and their won't be a shortage of takers as there is no current standard of care. Suggest you get of your lazy fat ass and talk to management for yourself.

TRT is also very cheap having dropped from £1.40 to 67p. I have bought some and also rumours about a contract announcement, not sure how true that is.

After the first part of the trial we will either sign a licensing deal or get taken over if we see good safety and early signs of efficacy. That is what management have told me. We will not go it alone, so NO dilution.

Fully funded for first part of trial. Kn@b

I'm not even thinking as far as phase 3 trials as I am absolutely convinced that if in the first part of the phase 2 trial we see good safety and early signs of efficacy then we will either get taken over or we will sign a licensing deal for mega bucks. As their is no current standard of care for Glioblastoma we will be in demand.

You are right pal it was £18.00, put dot in wrong place but Mcap is correct. Considering this is a registration grade phase 2 trial then you can see what will happen if we announce good safety and early signs of efficacy.

A few big months coming up starting this month with FDA ODD which is imminent. The first patient treated next month.

If I remember correctly Hemo was a phase 1 trial and ours is a registration grade phase 2 trial. When Hemo announced that first couple of patients had seen seen good safety and early signs of efficacy their share price jumped to £1.80 and had a Mcap of over £100M.

The next news here should be the FDA ODD, that should be anytime now as it was submitted late October. If granted and I can think of no reason why it wouldn’t be as we have already received the equivalent from the MHRA, can see it spiking on the day. Hopefully volume that day will clear the last few placing shares.

There is no delay to the start of the trial. The company have confirmed the trial will start in Q1 and most likely in March. Not sure where you have heard that it is delayed.

A decent write up on CRTX, see link below.

https://t.co/d1MXgOtORC

I hope you are correct about the increase in bioavailability as that would be some result and considering the huge market for GLP-1 drugs. I must admit the tone of the email to me from Sarah was quite buoyant without giving anything away. I’m pretty confident we will get an update this month.

Had it confirmed by Sarah that data from the in vivo trials will be announced in the new year. I also think we will get an update on the co development work for AT278 at the same time.

Also Arecor and Sequel Med Tech will be hosting a fireside discussion on the 7th January.